DNLI
What one share of Denali Therapeutics holds
Biological Products, (No Diagnostic Substances)
Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases.
Denali Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$2.83 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.42 |
| Cash and investments | $5.88 |
| Book value | $5.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$13.49 | $0.95 | −$12.15 | — | −$14.65 |
| 2017 | $0.00 | −$5.89 | $0.19 | −$5.31 | — | — |
| 2018 | $1.39 | −$0.39 | $0.04 | $0.50 | — | $5.78 |
| 2019 | $0.28 | −$2.07 | $0.19 | −$1.77 | — | $4.11 |
| 2020 | $2.98 | $0.63 | $0.03 | $3.67 | — | $9.55 |
| 2021 | $0.40 | −$2.39 | $0.07 | −$1.81 | — | $7.87 |
| 2022 | $0.86 | −$2.60 | $0.14 | −$2.09 | — | $7.67 |
| 2023 | $2.41 | −$1.06 | $0.09 | −$2.70 | — | $7.45 |
| 2024 | $0.00 | −$2.57 | $0.10 | −$2.21 | — | $8.53 |
| 2025 | $0.00 | −$2.97 | $0.06 | −$2.44 | — | $6.49 |